{
  "docId": "019dd923-622c-750b-8b98-08d95731b035",
  "docSlug": "4dea9707af58",
  "documentTitle": "AtriCure, Inc. (ATRC)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 23,
  "pageCount": 34,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a short-seller research note style to discredit the company's growth narrative and highlight the lack of operating leverage.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-08d95731b035/23",
  "deckHref": "/decks/019dd923-622c-750b-8b98-08d95731b035",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-08d95731b035.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-08d95731b035#slide-23",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Oddly, such near-total dominance of open-heart ablation has not led to any profits.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0396-73da-b906-9d8c3d71749b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.766,
        "x": 0.117,
        "y": 0.343
      },
      "kind": "paragraph",
      "text": "The obvious inference to be made from the STS data is that about a tenth of the approximately 285k patients undergoing open-heart surgeries annually suffer from preoperative AF...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20bb5452-81f9-4801-96c8-4e1a5eef1fdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.155,
        "w": 0.766,
        "x": 0.117,
        "y": 0.092
      },
      "kind": "paragraph",
      "text": "The biased and deeply flawed study of 2014 Medicare data says nothing useful about the company's TAM or the penetration rate of concomitant ablation...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a37ced98-09b9-4dc5-920f-d01c28752581",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.766,
        "x": 0.117,
        "y": 0.468
      },
      "kind": "paragraph",
      "text": "Based on our extensive discussions with cardiac surgeons, as well as the rapid revenue growth the product has generated, almost every single one of those procedures is accompanied by an exclusion of the patient's left atrial appendage...",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a415ff71-643a-4333-b99f-ad045fb5f459",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.095,
        "w": 0.766,
        "x": 0.117,
        "y": 0.593
      },
      "kind": "paragraph",
      "text": "Oddly, such near-total dominance of open-heart ablation has not led to any profits. On the contrary, AtriCure hasn't generated any free cash flow, or even positive EBITDA, since it went public in 2005.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d57f1813-2e4a-43a3-82a4-828082ae265d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.766,
        "x": 0.117,
        "y": 0.878
      },
      "kind": "source-note",
      "text": "20 AtriCure's most recent investor presentation implies an average sales price per concomitant ablation of approximately $3,000 - $3,500.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ae6a726-5b64-49f4-b548-613886dcaf4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.766,
        "x": 0.117,
        "y": 0.274
      },
      "kind": "title",
      "text": "Despite a decade of growth and market penetration, and little direct competition, AtriCure remains unprofitable",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d78f025-130a-44fe-83de-0a9775a6832e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}